General Information of Drug (ID: DM1Y69Q)

Drug Name
Interleukin-3 Drug Info
Indication
Disease Entry ICD 11 Status REF
Aplastic anemia 3A70 Approved [1]
Cross-matching ID
TTD Drug ID
DM1Y69Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eflapegrastim DMACVEI Neutropenia 4B00.0 Approved [3]
Efbemalenograstim DMDNJ18 Neutropenia 4B00.0 Approved [4]
Neugranin DMLRKJX Neutropenia 4B00.0 Preregistration [5]
DA-3031 DM6S4R2 Neutropenia 4B00.0 Phase 3 [6]
MK-4214 DMA25NO Neutropenia 4B00.0 Phase 3 [7]
LA-EP2006 DMI3YLK Neutropenia 4B00.0 Phase 3 [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Granulocyte colony-stimulating factor (CSF3) TT5TQ2W CSF3_HUMAN Modulator [2]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol. 1992 Apr;14(3):421-30.
3 Company report (Sppirx)
4 Clinical pipeline report, company report or official report of Generon (Shanghai) Corporation Ltd.
5 Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia pastoris. PLoS One. 2014; 9(12): e115840.
6 A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Invest New Drugs.2013 Oct;31(5):1300-6.
7 DOI: 10.1038/nbt0710-636a
8 National Cancer Institute Drug Dictionary (drug id 724518).